Based on the contribution of the work provided by the National Competent Authorities, any amended fee structure should reflect the right to an equitable proportion of that fee. This is emphasized by the HMA in response to the European Commissions public consultation on the revision of the fee regulation for pharmacovigilance activities.

The HMA response | pdf